CJC-1295 vs Tesamorelin + Ipamorelin
A side-by-side research comparison of CJC-1295 and Tesamorelin + Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Tesamorelin + Ipamorelin |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Tesamorelin/Ipamorelin Combination |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Compounded combination |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Tesamorelin stimulates GH release by activating GHRH receptors on pituitary somatotrophs. Ipamorelin amplifies the pulse by acting on ghrelin/GHS receptors. Together they produce a synergistic "1+1=3" GH release while maintaining physiological pulsatility. |
| Molecular weight | 3,368 Da (without DAC) | Blend |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | Tesamorelin: ~26 min; Ipamorelin: ~2 hours. Combined peak GH at 30-60 min post-injection. |
| Bioavailability | High (SubQ) | High (subcutaneous) |
| Typical dose | 100-300 mcg | Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg |
| Frequency | 1-3x daily (no-DAC) | Once daily (before bed) or twice daily |
| Route | Subcutaneous injection | Subcutaneous injection |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Tesamorelin + Ipamorelin reported benefits
- Significant fat loss (especially visceral/abdominal)
- Lean muscle gains
- Improved sleep quality
- Enhanced recovery
- Anti-aging effects
- Better body composition without exogenous HGH side effects
Related comparisons
Research and educational reference only. Not medical advice.